儿童中性粒细胞缺乏症伴发热的抗感染治疗方案选择及合理用药  

Anti-infective Treatment Options and Rational Drug Use in Children with Febrile Neutropenia

作　　者：尚飞能 卢金淼[1] 朱逸清[1] 宋芳 李智平[1] SHANG Feineng;LU Jinmiao;ZHU Yiqing;SONG Fang;LI Zhiping(Dept. of Pharmacy, National Children’s Medical Center/ Children’s Hospital of Fudan University, Shanghai 201102, China;Dept. of Pharmacy, Dehong People’s Hospital, Yunnan Dehong 678400, China)

机构地区：[1]国家儿童医学中心/复旦大学附属儿科医院临床药学部,上海201102 [2]德宏州人民医院药剂科,云南德宏678400

出　　处：《中国医院用药评价与分析》2020年第7期889-892,896,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：上海市科学技术委员会科研计划项目(No.19XD1400900);上海市重要薄弱学科建设项目(No.2016ZB0305)。

摘　　要：儿童中性粒细胞缺乏症伴发热期间易合并重症感染,治疗延误可能增加死亡概率,因此,在没有明确病原菌时,及时的广谱抗菌治疗至关重要。本文通过复习国内外指南及相关文献,从合理使用抗菌药物角度对儿童中性粒细胞缺乏症伴发热的管理以及经验抗感染治疗进行系统阐述,以期为临床合理使用抗菌药物,减少耐药菌的出现,减少药物的成本和副作用提供参考。Children with febrile neutropenia(FN)are prone to severe infections,and the treatment delay may increase mortality.Therefore,timely initiation of empirical broad-spectrum antibiotics therapy is of utmost importance with FN,even if there is no evidence for a documented infection.Through reviewing the domestic and foreign guidelines and related literature,the management of FN in children and the experience of anti-infective treatment were systematically described from the perspective of rational use of antibiotics,so as to provide reference for the rational use of antibiotics in clinical practice,to minimize the emergence of multi-drug resistant(MDR)bacteria and to reduce the costs and adverse drug reactions of these drugs.

关 键 词：儿童 中性粒细胞缺乏症 发热 抗菌药物 

分 类 号：R978.1[医药卫生—药品]